Davidson Investment Advisors Invests $329,000 in Amgen Inc. (NASDAQ:AMGN)

Davidson Investment Advisors bought a new stake in Amgen Inc. (NASDAQ:AMGNFree Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,223 shares of the medical research company’s stock, valued at approximately $329,000.

Several other large investors also recently bought and sold shares of AMGN. Claro Advisors LLC grew its stake in Amgen by 6.9% during the 2nd quarter. Claro Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $415,000 after purchasing an additional 120 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. lifted its holdings in shares of Amgen by 3.8% in the second quarter. Tokio Marine Asset Management Co. Ltd. now owns 11,012 shares of the medical research company’s stock valued at $2,445,000 after buying an additional 402 shares during the period. Reuter James Wealth Management LLC lifted its holdings in shares of Amgen by 48.0% during the second quarter. Reuter James Wealth Management LLC now owns 4,363 shares of the medical research company’s stock valued at $969,000 after purchasing an additional 1,416 shares during the last quarter. Nicolet Advisory Services LLC lifted its holdings in shares of Amgen by 4.4% during the third quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock valued at $745,000 after purchasing an additional 117 shares during the last quarter. Finally, Fortune Financial Advisors LLC purchased a new stake in shares of Amgen during the second quarter valued at $230,000. Institutional investors and hedge funds own 74.44% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 2,096 shares of Amgen stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $273.03, for a total transaction of $572,270.88. Following the completion of the transaction, the senior vice president now directly owns 10,874 shares of the company’s stock, valued at approximately $2,968,928.22. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on AMGN. SVB Leerink lowered Amgen from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $324.00 to $318.00 in a research report on Wednesday. Daiwa Capital Markets upgraded Amgen from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $264.00 to $320.00 in a research report on Thursday, December 21st. The Goldman Sachs Group increased their target price on Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a report on Wednesday. Argus raised their price target on Amgen from $280.00 to $310.00 and gave the company a “buy” rating in a report on Tuesday, October 17th. Finally, Morgan Stanley dropped their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a report on Wednesday. One analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $295.30.

Check Out Our Latest Report on AMGN

Amgen Stock Down 1.4 %

Shares of NASDAQ AMGN traded down $4.00 on Friday, reaching $290.85. 845,553 shares of the company’s stock traded hands, compared to its average volume of 2,942,241. The business’s 50 day simple moving average is $294.92 and its two-hundred day simple moving average is $273.81. Amgen Inc. has a 12 month low of $211.71 and a 12 month high of $329.72. The company has a quick ratio of 2.56, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The company has a market cap of $155.66 billion, a price-to-earnings ratio of 23.62, a price-to-earnings-growth ratio of 2.67 and a beta of 0.62.

Amgen (NASDAQ:AMGNGet Free Report) last issued its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. During the same quarter last year, the company posted $4.09 earnings per share. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. As a group, equities research analysts forecast that Amgen Inc. will post 19.68 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 7th. Shareholders of record on Friday, February 16th will be issued a $2.25 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.13. This represents a $9.00 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date is Thursday, February 15th. Amgen’s payout ratio is currently 68.21%.

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.